RE:RE:ONCY announces Pelareorep ≥50% ORR & mPFS Improvements BRACELET-1's Phase 2 results in a randomized setting that provided significant evidence of pelareorep's ability to produce significant ORR and PFS improvements over the control arm and meaningful clinical benefit in HR+/HER2- breast cancer patients sets the stage for an accelerated approval request in concert with the commencement of a Phase 3 registration study in this partciular indication.